Emerging role of pemetrexed in ovarian cancer

Federica Tomao, Pierluigi Benedetti Panici, Luigi Frati, Silverio Tomao

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The current treatment of choice of epithelial ovarian cancer involves aggressive tumor cytoreductive surgery followed by platinum- and taxane-based chemotherapy; however, despite the encouraging activity of these agents, most ovarian carcinomas relapse and many patients die from drug-resistant disease. After the failure of platinum- and taxane-based schedules, several cytotoxic agents have demonstrated activity in advanced ovarian cancer but none were able to induce significant and durable responses. Among the new cytotoxic agents, pemetrexed plays an emerging role in different tumors, demonstrating competitive activity and a promising safety profile. In ovarian cancer, pemetrexed has been investigated, with encouraging results, as a single agent and in association with platinum compounds; moreover, the drug has shown interesting activity both in platinum-sensitive and platinum-resistant ovarian cancer. According to these clinical results it appears reasonable to explore the combination of pemetrexed with other cytotoxic agents and also with targeted therapies in relapsed ovarian cancer patients.

Original languageEnglish
Pages (from-to)1727-1735
Number of pages9
JournalExpert Review of Anticancer Therapy
Volume9
Issue number12
DOIs
Publication statusPublished - Dec 2009

Fingerprint

Pemetrexed
Platinum
Ovarian Neoplasms
Cytotoxins
Platinum Compounds
Pharmaceutical Preparations
Neoplasms
Appointments and Schedules
Carcinoma
Safety
Recurrence
Drug Therapy
Therapeutics

Keywords

  • Carboplatin
  • Chemotherapy
  • Cisplatin
  • Epithelial ovarian cancer
  • Overall survival
  • Pemetrexed
  • Recurrent disease
  • Response rate
  • Targeted therapies
  • Taxanes

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Emerging role of pemetrexed in ovarian cancer. / Tomao, Federica; Panici, Pierluigi Benedetti; Frati, Luigi; Tomao, Silverio.

In: Expert Review of Anticancer Therapy, Vol. 9, No. 12, 12.2009, p. 1727-1735.

Research output: Contribution to journalArticle

Tomao, Federica ; Panici, Pierluigi Benedetti ; Frati, Luigi ; Tomao, Silverio. / Emerging role of pemetrexed in ovarian cancer. In: Expert Review of Anticancer Therapy. 2009 ; Vol. 9, No. 12. pp. 1727-1735.
@article{03a7b788b9d44a4c9960043201764048,
title = "Emerging role of pemetrexed in ovarian cancer",
abstract = "The current treatment of choice of epithelial ovarian cancer involves aggressive tumor cytoreductive surgery followed by platinum- and taxane-based chemotherapy; however, despite the encouraging activity of these agents, most ovarian carcinomas relapse and many patients die from drug-resistant disease. After the failure of platinum- and taxane-based schedules, several cytotoxic agents have demonstrated activity in advanced ovarian cancer but none were able to induce significant and durable responses. Among the new cytotoxic agents, pemetrexed plays an emerging role in different tumors, demonstrating competitive activity and a promising safety profile. In ovarian cancer, pemetrexed has been investigated, with encouraging results, as a single agent and in association with platinum compounds; moreover, the drug has shown interesting activity both in platinum-sensitive and platinum-resistant ovarian cancer. According to these clinical results it appears reasonable to explore the combination of pemetrexed with other cytotoxic agents and also with targeted therapies in relapsed ovarian cancer patients.",
keywords = "Carboplatin, Chemotherapy, Cisplatin, Epithelial ovarian cancer, Overall survival, Pemetrexed, Recurrent disease, Response rate, Targeted therapies, Taxanes",
author = "Federica Tomao and Panici, {Pierluigi Benedetti} and Luigi Frati and Silverio Tomao",
year = "2009",
month = "12",
doi = "10.1586/ERA.09.141",
language = "English",
volume = "9",
pages = "1727--1735",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "12",

}

TY - JOUR

T1 - Emerging role of pemetrexed in ovarian cancer

AU - Tomao, Federica

AU - Panici, Pierluigi Benedetti

AU - Frati, Luigi

AU - Tomao, Silverio

PY - 2009/12

Y1 - 2009/12

N2 - The current treatment of choice of epithelial ovarian cancer involves aggressive tumor cytoreductive surgery followed by platinum- and taxane-based chemotherapy; however, despite the encouraging activity of these agents, most ovarian carcinomas relapse and many patients die from drug-resistant disease. After the failure of platinum- and taxane-based schedules, several cytotoxic agents have demonstrated activity in advanced ovarian cancer but none were able to induce significant and durable responses. Among the new cytotoxic agents, pemetrexed plays an emerging role in different tumors, demonstrating competitive activity and a promising safety profile. In ovarian cancer, pemetrexed has been investigated, with encouraging results, as a single agent and in association with platinum compounds; moreover, the drug has shown interesting activity both in platinum-sensitive and platinum-resistant ovarian cancer. According to these clinical results it appears reasonable to explore the combination of pemetrexed with other cytotoxic agents and also with targeted therapies in relapsed ovarian cancer patients.

AB - The current treatment of choice of epithelial ovarian cancer involves aggressive tumor cytoreductive surgery followed by platinum- and taxane-based chemotherapy; however, despite the encouraging activity of these agents, most ovarian carcinomas relapse and many patients die from drug-resistant disease. After the failure of platinum- and taxane-based schedules, several cytotoxic agents have demonstrated activity in advanced ovarian cancer but none were able to induce significant and durable responses. Among the new cytotoxic agents, pemetrexed plays an emerging role in different tumors, demonstrating competitive activity and a promising safety profile. In ovarian cancer, pemetrexed has been investigated, with encouraging results, as a single agent and in association with platinum compounds; moreover, the drug has shown interesting activity both in platinum-sensitive and platinum-resistant ovarian cancer. According to these clinical results it appears reasonable to explore the combination of pemetrexed with other cytotoxic agents and also with targeted therapies in relapsed ovarian cancer patients.

KW - Carboplatin

KW - Chemotherapy

KW - Cisplatin

KW - Epithelial ovarian cancer

KW - Overall survival

KW - Pemetrexed

KW - Recurrent disease

KW - Response rate

KW - Targeted therapies

KW - Taxanes

UR - http://www.scopus.com/inward/record.url?scp=73349089623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73349089623&partnerID=8YFLogxK

U2 - 10.1586/ERA.09.141

DO - 10.1586/ERA.09.141

M3 - Article

VL - 9

SP - 1727

EP - 1735

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 12

ER -